Advertisement
Research Article Free access | 10.1172/JCI108991
Departments of Medicine of Robert B. Brigham Hospital, Boston, Massachusetts 02120
Massachusetts General Hospital, Boston, Massachusetts 02114
Harvard Medical School, Boston, Massachusetts 02115
Department of Pharmacology of the Harvard School of Dental Medicine, Boston, Massachusetts 02115
Find articles by Goetzl, E. in: JCI | PubMed | Google Scholar
Departments of Medicine of Robert B. Brigham Hospital, Boston, Massachusetts 02120
Massachusetts General Hospital, Boston, Massachusetts 02114
Harvard Medical School, Boston, Massachusetts 02115
Department of Pharmacology of the Harvard School of Dental Medicine, Boston, Massachusetts 02115
Find articles by Tashjian, A. in: JCI | PubMed | Google Scholar
Departments of Medicine of Robert B. Brigham Hospital, Boston, Massachusetts 02120
Massachusetts General Hospital, Boston, Massachusetts 02114
Harvard Medical School, Boston, Massachusetts 02115
Department of Pharmacology of the Harvard School of Dental Medicine, Boston, Massachusetts 02115
Find articles by Rubin, R. in: JCI | PubMed | Google Scholar
Departments of Medicine of Robert B. Brigham Hospital, Boston, Massachusetts 02120
Massachusetts General Hospital, Boston, Massachusetts 02114
Harvard Medical School, Boston, Massachusetts 02115
Department of Pharmacology of the Harvard School of Dental Medicine, Boston, Massachusetts 02115
Find articles by Austen, K. in: JCI | PubMed | Google Scholar
Published March 1, 1978 - More info
A peptide of approximately 300-400 daltons exhibiting in vitro chemotactic activity for human polymorphonuclear (PMN) leukocytes, with a preference for the eosinophil series, was isolated from extracts of anaplastic lung carcinomas of the large squamous cell type obtained from three patients with marked peripheral blood hypereosinophilia and eosinophilic infiltration of the tumors and surrounding normal pulmonary tissues. This chemotactic factor was termed ECF-LSC (eosinophil chemotactic factor of lung squamous cell carcinoma). ECF-LSC appeared in the urine of two of the patients in increasing quantities late in the course of their disease and was also elaborated by long-term cultures of dispersed tumor cells from the same two patients. Three anaplastic large cell bronchogenic carcinomas which were not associated with tumor tissue or peripheral blood eosinophilia, a bronchogenic adenocarcinoma from a patient with only peripheral eosinophilia, and a renal cell carcinoma metastatic to the lungs and associated with transient pleural tissue and fluid eosinophilia were all devoid of ECF-LSC. ECF-LSC from tumor tissue extracts, urine, and tumor cell culture medium was comparable to the mast cell-associated tetrapeptides of the eosinophil chemotactic factor of anaphylaxis (ECF-A) in size, but eluted from Dowex-1 at pH 5.0-3.5 in contrast to the more acidic ECF-A tetrapeptides which eluted at pH 3.2-2.2 ECF-LSC, like the tetrapeptides of ECF-A, had a secondary chemotactic activity for neutrophil PMN leukocytes, but not mononuclear leukocytes, and deactivated both eosinophil and neutrophil PMN leukocytes so that they would not respond to a subsequent in vitro chemotactic stimulus. Eosinophils from the two patients with urinary excretion of ECF-LSC and the highest concentrations in tumor extracts were hyporesponsive in vitro to homologous and heterologous chemotactic stimuli, suggesting that ECF-LSC had deactivated the eosinophils in vivo.